Cited by 1,099Tuberous Sclerosis Complex ResearchVascular Malformations and HemangiomasPulmonary Hypertension Research and Treatments

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

Open access

McCormack, Francis X., Inoue, Yoshikazu, Moss, Joel, Singer, Lianne G., Strange, Charlie, Nakata, Koh, Barker, Alan F., Chapman, Jeffrey T., Brantly, Mark L., Stocks, James M., Brown, Kevin K., Lynch, Joseph P., Goldberg, Hilary J., Young, Lisa R., Kinder, Brent W., Downey, Gregory P., Sullivan, Eugene J., Colby, Thomas V., McKay, Roy T., Cohen, Marsha M., Korbee, Leslie, Taveira-DaSilva, Angelo M., Lee, Hye-Seung, Krischer, Jeffrey P., Trapnell, Bruce C.·2011·New England Journal of Medicine

DOI 10.1056/nejmoa1100391PMC PMC3118601

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM. METHODS: We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment--a 12-month randomized, double-blind comparison of sirolimus with placebo, followed by a 12-month observation period. The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory volume in 1 second (FEV(1)). RESULTS: During the treatment period, the FEV(1) slope was -12±2 ml per month in the placebo group (43 patients) and 1±2 ml per month in the sirolimus group (46 patients) (P<0.001). The absolute between-group difference in the mean change in FEV(1) during the treatment period was 153 ml, or approximately 11% of the mean FEV(1) at enrollment. As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance. There was no significant between-group difference in this interval in the change in 6-minute walk distance or diffusing capacity of the lung for carbon monoxide. After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group. Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups. CONCLUSIONS: In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life. Therapy with sirolimus may be useful in selected patients with LAM. (Funded by the National Institutes of Health and others; MILES ClinicalTrials.gov number, NCT00414648.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1100391

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,275
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,250
Self-citation
A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 674
Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis
Carsillo, T., Astrinidis, A., & Henske, E. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6085 · Cited by 648
Minimal Clinically Important Differences in COPD Lung Function
Donohue, J. F. (2005) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200053377 · Cited by 525
The truly remarkable universality of half a standard deviation: confirmation through another look
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2004) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.4.5.581 · Cited by 490
The NHLBI Lymphangioleiomyomatosis Registry
Ryu, J. H., Moss, J., Beck, G. J., Lee, J.-C., Brown, K. K., Chapman, J. T., Finlay, G. A., Olson, E. J., Ruoss, S. J., MAURER, J. R., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200409-1298oc · Cited by 466
Self-citation
Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation
Goncharova, E., Goncharov, D. A., Eszterhas, A., Hunter, D., Glassberg, M., Yeung, R. S., Walker, C., Noonan, D., Kwiatkowski, D., Chou, M. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202678200 · Cited by 433
Pulmonary Lymphangioleiomyomatosis: A Study of 69 Patients
Urban, T., Lazor, R., Lacronique, J., Murris, M., Labrune, S., & Valeyre, D. (1999) · Medicine · doi:10.1097/00005792-199909000-00004 · Cited by 327
Lymphangioleiomyomatosis
McCormack, F. X. (2008) · CHEST Journal · doi:10.1378/chest.07-0898 · Cited by 303
Self-citation

Flagged first, then by citations

Show all 27 references

Research works printed but not linked: 1

Khanna D, 2010, Clin Exp Rheumatol, 28, S55

Sorted by citations

Items 501–600 of 999

A Retrospective Study of Lung Transplantation in Patients With Lymphangioleiomyomatosis: Challenges and Outcomes
Zhang, J., Liu, D., Yue, B., Ban, L., Zhou, M., Wang, H., Lv, J., Wu, B., Zhai, Z., Xu, K., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.584826 · Cited by 11
CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis
Evans, J. F., Obraztsova, K., Lin, S. M., & Krymskaya, V. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052233 · Cited by 11
The paradox of autophagy in Tuberous Sclerosis Complex
Reis, L. B., Filippi‐Chiela, E. C., Ashton‐Prolla, P., Visioli, F., & Rosset, C. (2021) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2020-0014 · Cited by 11
Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway
Makovski, V., Jacob‐Hirsch, J., Gefen-Dor, C., Shai, B., Ehrlich, M., Rechavi, G., & Kloog, Y. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.502 · Cited by 11
Mitochondrial metabolic rewiring sensitizes mTORC1 inhibitor persister cells to cuproptosis
Du, H., Liu, H.-J., Łośko, M., Yang, Y. C., Yuan, M., Henske, E. P., Asara, J. M., Singh, M., & Kwiatkowski, D. J. (2025) · JCI Insight · doi:10.1172/jci.insight.187448 · Cited by 10
The Lung Transplant Candidate, Indications, Timing, and Selection Criteria
Mannem, H. C., Aversa, M. M., Keller, T., & Kapnadak, S. G. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.10.001 · Cited by 10
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet
Gibbons, E., Minor, B., & Hammes, S. R. (2023) · Endocrine Related Cancer · doi:10.1530/erc-23-0102 · Cited by 10
Effects of Sirolimus on Anti-SARS-CoV-2 Vaccination in Patients With Lymphangioleiomyomatosis
Worthy, T., Jones, A. D., Yang, B. E., Ishiwata-Endo, H., Gupta, N., & Moss, J. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.09.014 · Cited by 10
Self-citation
Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis
Evans, J. F., McCormack, F. X., Sonenberg, N., & Krymskaya, V. P. (2023) · European Respiratory Review · doi:10.1183/16000617.0100-2023 · Cited by 10
Self-citation
Tenacissoside H repressed the progression of glioblastoma by inhibiting the PI3K/Akt/mTOR signaling pathway
Dong, J., Qian, Y., Zhang, W., Xu, J., Wang, L., Fan, Z., Jia, M., Wei, L., Yang, H., Luo, X., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176401 · Cited by 10
Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study
Harari, S. A., Elia, D., Caminati, A., Geginat, J., Luisi, F., Pelosi, G., Specchia, C., Torre, O., Trevisan, R., Vasco, C., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00217-0 · Cited by 12
The Bi-steric Inhibitor RMC-5552 Reduces mTORC1 Signaling and Growth in Lymphangioleiomyomatosis
Evans, J. F., Ledwell, O. A., Tang, Y., Rue, R. W., Mukhitov, A. R., Diesler, R., Lin, S. M., Vanka, K. S., Basil, M. C., Cantu, E., et al. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0242oc · Cited by 10
Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue
Espín, R., Baiges, A., Blommaert, E., Herranz, C., Román, A., Sáez, B., Ancochea, J., Valenzuela, C., Ussetti, P., Laporta, R., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0220 · Cited by 10
Self-citation
LAM Cells as Potential Drivers of Senescence in Lymphangioleiomyomatosis Microenvironment
Bernardelli, C., Ancona, S., Lazzari, M., Lettieri, A., Selvaggio, P., Massa, V., Gervasini, C., Marco, F. D., Chiaramonte, R., & Lesma, E. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137040 · Cited by 10
A multi‑omics study of diagnostic markers and the unique inflammatory tumor micro‑environment involved in tuberous sclerosis complex‑related renal angiomyolipoma
Wang, Z., Liu, X., Wang, W., Wei, J., Seery, S., Xu, J., Sun, H., Yu, Y., Zhao, Y., Wang, X., et al. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5422 · Cited by 10
Activation of the Mammalian Target of Rapamycin in the Rostral Ventromedial Medulla Contributes to the Maintenance of Nerve Injury-Induced Neuropathic Pain in Rat
Wang, J., Feng, D., Li, Z., Feng, B., Zhang, H., Zhang, T., Chen, T., & Li, Y.-Q. (2015) · Neural Plasticity · doi:10.1155/2015/394820 · Cited by 10
Development of a Lymphangioleiomyomatosis Model by Endonasal Administration of Human TSC2−/− Smooth Muscle Cells in Mice
Lesma, E. A., Chiaramonte, E., Isaia, E., Grande, V., Ancona, S., Orpianesi, E., Giulio, A. M. D., & Gorio, A. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.05.017 · Cited by 10
Treatment of lymphangioleiomyomatosis: building evidence in orphan diseases
Cottin, V. (2014) · European Respiratory Journal · doi:10.1183/09031936.00025314 · Cited by 10
Isolation of individual cellular components from lung tissues of patients with lymphangioleiomyomatosis
Ando, K., Fujino, N., Mitani, K., Ota, C., Okada, Y., Kondo, T., Mizobuchi, T., Kurihara, M., Suzuki, K., Hoshika, Y., et al. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00365.2015 · Cited by 10
Sirolimus monotherapy for Erdheim–Chester disease
van Bommel, E. F. H., van der Zijden, M. A., Gregoor, P. J. H. S., Hendriksz, T. R., Ho-Han, S. H., & Westenend, P. J. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1589648 · Cited by 10
Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study
Kim, C., Do, K., Cha, J., Song, J. W., Lee, S. M., & Lee, K. Y. (2019) · European Radiology · doi:10.1007/s00330-019-06412-4 · Cited by 10
Clinical features of 18 perivascular epithelioid cell tumor cases
Jia, R., Jiang, L., Zhou, Y., Wang, Y., Guo, X., Ji, Y., Ni, X., & Yang, X. (2020) · Medicine · doi:10.1097/md.0000000000021659 · Cited by 10
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Lu, Y., Zhang, E. Y., Liu, J., & Yu, J. J. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01490-w · Cited by 10
A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics
Das, R., Choithramani, A., & Shard, A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.12.009 · Cited by 10
Multiple Perivascular Epithelioid Cell Tumors: Clear Cell Tumor of the Lung Accompanied by Angiomyolipoma of the Liver
Neri, S., Ishii, G., Aokage, K., Hishida, T., Yoshida, J., Nishimura, M., & Nagai, K. (2013) · Annals of Thoracic and Cardiovascular Surgery · doi:10.5761/atcs.cr.12.02179 · Cited by 10
Prevalence and clinical features of lymphedema in patients with lymphangioleiomyomatosis
Hoshika, Y., Hamamoto, T., Sato, K., Eto, H., Kuriyama, S., Yoshimi, K., Iwakami, S., Takahashi, K., & Seyama, K. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.04.022 · Cited by 10
Linfangioleiomiomatosis: novedades terapéuticas
Casanova, Á., & Ancochea, J. (2011) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2011.06.008 · Cited by 10
Lymphangioleiomyomatosis: New Therapeutic Approaches
Casanova, Á., & Ancochea, J. (2011) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2011.06.016 · Cited by 10
Lymphangioleiomyomatosis: an explosive presentation of a rare disease
Pais, F. M., Fayed, M., & Evans, T. (2017) · Oxford Medical Case Reports · doi:10.1093/omcr/omx023 · Cited by 10
[18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Verwer, E. E., Kavanagh, T. R., Mischler, W. J., Feng, Y., Takahashi, K., Wang, S., Shoup, T. M., Neelamegam, R., Yang, J., Guehl, N. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3693 · Cited by 10
Lymphangioleiomyomatosis
Johnson, S. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_19 · Cited by 10
Zoledronic acid inhibits TSC2-null cell tumor growth via RhoA/YAP signaling pathway in mouse models of lymphangioleiomyomatosis
Zhao, D., Wu, J., Zhao, Y., Shao, W., Cheng, Q., Shao, X., Yuan, X., Ye, J., Gao, J., Jin, M., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1131-4 · Cited by 10
Rare genetic interstitial lung diseases: a pictorial essay
Borie, R., Berteloot, L., Kannengiesser, C., Griese, M., Cazes, A., Crestani, B., Hadchouel, A., & Debray, M. (2024) · European Respiratory Review · doi:10.1183/16000617.0101-2024 · Cited by 10
Targeting fibroblast–endothelial cell interactions in LAM pathogenesis using 3D spheroid models and spatial transcriptomics
Koç-Günel, S., Liu, E. C., Gautam, L. K., Calvert, B. A., Murthy, S., Harriott, N. C., Nawroth, J. C., Zhou, B., Krymskaya, V. P., & Ryan, A. L. (2025) · JCI Insight · doi:10.1172/jci.insight.187899 · Cited by 12
Treatment Option(s) for Pulmonary Lymphangioleiomyomatosis: Progress and Current Challenges
Krymskaya, V. P. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0381ed · Cited by 9
Rapamycin Exacerbates Cardiovascular Dysfunction after Complete High-Thoracic Spinal Cord Injury
Eldahan, K. C., Cox, D. H., Gollihue, J. L., Patel, S. P., & Rabchevsky, A. G. (2017) · Journal of Neurotrauma · doi:10.1089/neu.2017.5184 · Cited by 10
Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex
Wang, F., Chen, X.-T., Li, C., Sun, Q., Chen, Y., Wang, Y., Peng, H., LIU, Z.-L., Chen, R., Liu, K.-Y., et al. (2013) · Oncogene · doi:10.1038/onc.2013.401 · Cited by 9
Intracrine steroid production and mammalian target of rapamycin pathways in pulmonary lymphangioleiomyomatosis
Adachi, K., Miki, Y., Saito, R., Hata, S., Yamauchi, M., Mikami, Y., Okada, Y., Seyama, K., Kondo, T., & Sasano, H. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.02.019 · Cited by 9
Rapamycin Treatment for Benign Multicystic Peritoneal Mesothelioma: A Rare Disease with a Difficult Management
Stallone, G., Infante, B., Cormio, L., Macarini, L., & Grandaliano, G. (2017) · American Journal of Case Reports · doi:10.12659/ajcr.903548 · Cited by 9
Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis
Lin, Y., Yu, C., Tu, Y., & Chi, C. (2022) · Biomedicines · doi:10.3390/biomedicines10040826 · Cited by 9
How Much Would You Give to Save a Dying Bird? Patient Advocacy and Biomedical Research
Rosenbaum, L. R. (2012) · New England Journal of Medicine · doi:10.1056/nejmms1207114 · Cited by 9
SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.
Hečimović, A., Jakopović, M., Pavliša, G., Makek, M. J., Vukić-Dugac, A., Redžepi, G., Brcic, L., Samaržija, M., & Gupta, N. (2015) · PubMed · Cited by 9
Lymphangioléiomyomatose pulmonaire : de la physiopathologie à la prise en charge
Chebib, N., Khouatra, C., Lazor, R., Archer, F., Leroux, C., Gamondes, D., Thivolet-Béjui, F., Cordier, J. F., & Cottin, V. (2015) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2015.10.005 · Cited by 9
mTORC1 signaling in primary central nervous system lymphoma
Nitta, N., Nakasu, S., Shima, A., & Nozaki, K. (2016) · Surgical Neurology International · doi:10.4103/2152-7806.185781 · Cited by 9
Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis
Steagall, W. K., Stylianou, M. P., Pacheco–Rodriguez, G., & Moss, J. (2019) · JCI Insight · doi:10.1172/jci.insight.126703 · Cited by 9
Self-citation
Quantitative Analysis of Cystic Lung Diseases by Use of Paired Inspiratory and Expiratory CT: Estimation of the Extent of Cyst-Airway Communication and Evaluation of Diagnostic Utility
Suzuki, K., Seyama, K., Ebana, H., Kumasaka, T., & Kuwatsuru, R. (2020) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.2020190097 · Cited by 9
Doxycycline reduces the migration of tuberous sclerosis complex‐2 null cells ‐ effects on RhoA‐ GTP ase and focal adhesion kinase
Ng, H. Y., Oliver, B. G. G., Burgess, J. K., Krymskaya, V. P., Black, J. L., & Moir, L. M. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12593 · Cited by 9
Doxycycline in lymphangioleiomyomatosis: not all questions are answered
Baldi, B. G., & de Carvalho, C. R. R. (2014) · European Respiratory Journal · doi:10.1183/09031936.00008114 · Cited by 9
Disorders of the Lymphatic System
Mortimer, P. S., & Gordon, K. D. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook103 · Cited by 9
Modulation of infiltrating CD206 + macrophages restricts progression of pulmonary lymphangioleiomyomatosis
Liu, H.-J., Diesler, R., Chami, J., Wu, B., Du, H., Jin, Y., Daou, M., Alesi, N., Khabibullin, D., Leroux, C., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.00084-2025 · Cited by 8
Hyperactivation of mTORC1 signaling mediates folliculin deficiency–induced pulmonary cyst formation in Birt-Hogg-Dubé syndrome
Cao, K. X., Chen, H., Chu, L., Wang, H.-J., Zhang, J., Luo, Y., Chiu, J. W. Y., Khabibullin, D., Alesi, N., Thornton, M. E., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194300 · Cited by 9
Self-citation
Histology-Specific Therapy for Advanced Soft Tissue Sarcoma and Benign Connective Tissue Tumors
Silk, A. W., & Schuetze, S. M. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0194-4 · Cited by 8
Rapid oral desensitization to sirolimus in a patient with lymphangioleiomyomatosis
Sebaaly, J. C., Bowers, L., Mazur, J., Kotloff, R., Olmsted, B. R., Kaplan, A. P., & Strange, C. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.11.007 · Cited by 8
Self-citation
Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor
Evans, J. F., Rue, R. W., Mukhitov, A. R., Obraztsova, K., Smith, C. J., & Krymskaya, V. P. (2019) · Biomolecules · doi:10.3390/biom10010028 · Cited by 7
The effects of total pleural covering on pneumothorax recurrence and pulmonary function in lymphangioleiomyomatosis patients without history of pleurodesis or thoracic surgeries for pneumothorax
Suzuki, E., Kurihara, M., Tsuboshima, K., Watanabe, K., Okamoto, S., & Seyama, K. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-2286 · Cited by 7
A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant
Warrior, K., Leard, L. E., Nair, A., Gries, C., Fisher, A. J., Johnson, S. R., McCormack, F. X., & Dilling, D. F. (2022) · Respiratory Medicine · doi:10.1016/j.rmed.2022.106779 · Cited by 8
Self-citation
A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs
Prosdocimi, M., Zuccato, C., Cosenza, L. C., Borgatti, M., Lampronti, I., Finotti, A., & Gambari, R. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17845.1 · Cited by 8
Pathology of hereditary renal cell carcinoma syndromes: Tuberous sclerosis complex (TSC)
Machacek, M. E., Wu, C., & Cornejo, K. M. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.09.001 · Cited by 8
Kaposiform Hemangioendothelioma: Therapeutic efficacy for an enigmatic diagnosis
Blei, F. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25365 · Cited by 8
Rare (pulmonary) disease day: “feeding the breath, energy for life!”
Harari, S. A., Lau, E., Tamura, Y., Cottin, V., Simonneau, G., & Humbert, M. J. C. (2015) · European Respiratory Journal · doi:10.1183/09031936.00221914 · Cited by 8
Genetic testing in diffuse parenchymal lung disease
Spagnolo, P., Luppi, F., Cerri, S., & Richeldi, L. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-79 · Cited by 8
Comorbid connective tissue diseases and autoantibodies in lymphangioleiomyomatosis: a retrospective cohort study
Futami, S., Arai, T., Hirose, M., Sugimoto, C., Ikegami, N., Akira, M., Kasai, T., Kitaichi, M., Hayashi, S., & Inoue, Y. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0933-0 · Cited by 8
Self-citation
Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report
Pluvy, J., Brosseau, S., Stelianides, S., Danel, C. J., Nguenang, M., Khalil, A., Crestani, B., Zalcman, G., & Gounant, V. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0775-5 · Cited by 8
Generalised mosaicism forTSC2mutation in isolated lymphangioleiomyomatosis
Ogórek, B., Hamieh, L., Lasseter, K. D., Bagwe, S., Machado, T. R., Herranz, C., Thorner, A. R., Nag, A., Gulleman, P. M., Giannikou, K., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.00938-2019 · Cited by 8
Self-citation
Power and sample-size calculations for trials that compare slopes over time: Introducing the slopepower command
Nash, S., Morgan, K. E., Frost, C. D., & Mulick, A. R. (2021) · The Stata Journal Promoting communications on statistics and Stata · doi:10.1177/1536867x211045512 · Cited by 8
Renal neoplasms in tuberous sclerosis mice are neurocristopathies
Unachukwu, U. J., Shiomi, T., Goldklang, M. P., Chada, K. K., & D'Armiento, J. M. (2021) · iScience · doi:10.1016/j.isci.2021.102684 · Cited by 8
Peripheral tissular analysis of rapamycin’s effect as a neuroprotective agent in vivo
González-Alcocer, A., Gopar‐Cuevas, Y., Soto‐Domínguez, A., Loera‐Arias, M. D. J., Cárdenas, O. S., Montes‐de‐Oca‐Luna, R., Rodríguez‐Rocha, H., & García‐García, A. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02276-6 · Cited by 8
Management of refractory chylothorax in pulmonary lymphangioleiomyomatosis
Ellender, C. M., Williams, T. J., Gooi, J. H., Snell, G. I., & Whitford, H. M. (2015) · Respirology Case Reports · doi:10.1002/rcr2.105 · Cited by 8
Establishment of Tsc2-deficient rat embryonic stem cells
ITO, Y., Kawano, H., Kanai, F., Nakamura, E., Tada, N., Takai, S., Horie, S., Arai, H., Kobayashi, T., & Hino, O. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2913 · Cited by 8
Imaging of Cystic Lung Disease
Gillott, M., Flemming, B. P., & Ravenel, J. G. (2014) · Seminars in Roentgenology · doi:10.1053/j.ro.2014.04.007 · Cited by 8
Massive fetal chylothorax successfully treated with postnatal talc pleurodesis: A case report and review of the literature
Hodges, M. M., Crombleholme, T. M., Meyers, M. L., Kulungowski, A. M., Marwan, A. I., Nakano, T. A., Behrendt, N. J., & Liechty, K. W. (2016) · Journal of Pediatric Surgery Case Reports · doi:10.1016/j.epsc.2016.03.014 · Cited by 8
Women’s Health and Lung Development and Disease
Kocurek, E. G., & Hemnes, A. R. (2016) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2016.01.003 · Cited by 7
Sirolimus for the treatment of lymphangioleiomyomatosis
Singla, A., Gupta, N., Apewokin, S. K., & McCormack, F. X. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1391089 · Cited by 8
Self-citation
Extrapulmonary uterine lymphangioleiomyomatosis (LAM) and dysfunctional uterine bleeding: the first presentation of LAM in a tuberous sclerosis complex patient
Grant, L., Chipwete, S. E., Hoo, S. S., & Bhatnagar, A. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-226358 · Cited by 8
Efficiency of sirolimus delivery to the skin is dependent on administration route and formulation
Kitayama, K., Maeda, S., Nakamura, A., Katayama, I., & Wataya‐Kaneda, M. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.05.002 · Cited by 8
Diffuse parenchymal lung disease
Maher, T. M. (2012) · Medicine · doi:10.1016/j.mpmed.2012.03.007 · Cited by 8
Chronic Sirolimus Therapy for Lymphangioleiomyomatosis
McCormack, F. X. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-2032ed · Cited by 8
Self-citation
ETV2 regulates PARP-1 binding protein to induce ER stress–mediated death in tuberin-deficient cells
Shrestha, S., Lamattina, A. M., Pacheco–Rodriguez, G., Ng, J., Liu, X., Sonawane, A. R., Imani, J., Qiu, W., Kosmas, K., Louis, P. H., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202201369 · Cited by 7
Self-citation
Systematic Review of Lymphangioleiomyomatosis Outcomes in Pregnancy and a Proposed Management Guideline
Champion, M. L., Maier, J. G., Bushman, E. T., Barney, J. B., Casey, B. M., & Sinkey, R. G. (2023) · American Journal of Perinatology · doi:10.1055/a-2051-8395 · Cited by 7
Ex Utero Intrapartum Treatment for Prenatally Diagnosed Cervicofacial Lymphatic Malformations
Gillipelli, S. R., Peiffer, S., Larabee, S. M., Ketwaroo, P. D., Rialon, K. L., Bedwell, J. R., Mehta, D., Lee, T. C., Keswani, S. G., & King, A. (2024) · Journal of Surgical Research · doi:10.1016/j.jss.2024.08.026 · Cited by 7
Phenotypes associated with inherited and developmental somatic mutations in genes encoding mTOR pathway components
Saxena, A., & Sampson, J. R. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.09.018 · Cited by 7
Coexistence of pulmonary lymphangioleiomyomatosis and pulmonary angiomyolipoma
Sun, X., Feng, R., Zhang, Y., Shi, J., & Xu, K. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0286-1 · Cited by 7
Analysis of a Mouse Skin Model of Tuberous Sclerosis Complex
Guo, Y., Dreier, J. R., Cao, J., Du, H., Granter, S. R., & Kwiatkowski, D. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167384 · Cited by 7
Targeted therapy for tuberous sclerosis complex
Белоусова, Е. Д., Владимирович, В. Д., Pivovarova, A. M., Katysheva, O., & Dorofeeva, M. Y. (2016) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2016-61-5-106-112 · Cited by 8
Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis
Sakurai, T., Arai, T., Hirose, M., Kojima, K., Sakamoto, T., Matsuda, Y., Sugimoto, C., Yoon, H., & Inoue, Y. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-02081-z · Cited by 7
Self-citation
Machine learning to distinguish lymphangioleiomyomatosis from other diffuse cystic lung diseases
Jonas, A. M., Muelly, M. C., Gupta, N., & Reicher, J. J. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.01.001 · Cited by 7
Soluble Immune-Related Proteins as New Candidate Serum Biomarkers for the Diagnosis and Progression of Lymphangioleiomyomatosis
Liu, X., Xu, Y., Wu, X., Liu, Y., Wu, Q., Wu, J., Zhang, H., Zhou, M., & Qu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844914 · Cited by 7
Long-term clinical course and progression of lymphangioleiomyomatosis in a single lung transplant referral centre in Korea
Chang, S., Choi, J. S., Leem, A. Y., Lee, S. H., Lee, S. H., Kim, S. Y., Chung, K. S., Jung, J. Y., Kang, Y. A., Kim, Y. S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12314-1 · Cited by 7
A Multi-Centric Study Assessing Safety and Efficacy of Everolimus in Adult Chinese Patients With Tuberous Sclerosis Complex Associated Renal Angiomyolipomas
Wang, W., Guo, G., Shi, G., Wei, X., Hu, Z., Li, H., Zhang, X., Ye, D., & Zhang, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871723 · Cited by 7
Progress in Tuberous Sclerosis Complex Renal Disease
Bissler, J. J., Batchelor, D., & Kingswood, J. C. (2022) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2022042857 · Cited by 7
Medical Treatment of Vascular Anomalies
DeMaio, A., New, C. M., & Bergmann, S. (2022) · Dermatologic Clinics · doi:10.1016/j.det.2022.06.013 · Cited by 7
Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors
Kumondai, M., Kikuchi, M., Mizuguchi, A., Hayashi, N., Ui, M., Hirama, T., Okada, Y., Sato, Y., Sato, T., Maekawa, M., et al. (2023) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2023.j016 · Cited by 7
Tyrosine Kinase Inhibitors Diminish Renal Neoplasms in a Tuberous Sclerosis Model Via Induction of Apoptosis
Unachukwu, U. J., Sonett, J., Woode, D. R., Shiomi, T., Chada, K. K., & D'Armiento, J. M. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0224 · Cited by 7
Down‐regulation of mitogen‐activated protein kinases and nuclear factor‐ κB signaling is involved in rapamycin suppression of TLR2‐induced inflammatory response in monocytic THP‐1 cells
Sun, R., Zhang, Y., Ma, S., Qi, H.-T., Wang, M., Duan, J.-H., Ma, S., Zhu, X., Li, G., & Wang, H. (2015) · Microbiology and Immunology · doi:10.1111/1348-0421.12321 · Cited by 7
Fibrose pulmonaire: dans quels cas et sur quels critères envisager une admission en réanimation ?
Mullier, A., Cottin, V., Richard, J., & Guérin, C. (2012) · Réanimation · doi:10.1007/s13546-012-0642-y · Cited by 8
Antibody αPEP13h Reacts With Lymphangioleiomyomatosis Cells in Lung Nodules
Valencia, J. C., Steagall, W. K., Zhang, Y., Fetsch, P. A., Abati, A. D., Tsukada, K., Billings, E. M., Hearing, V. J., Yu, Z., Pacheco–Rodriguez, G., et al. (2014) · CHEST Journal · doi:10.1378/chest.14-0380 · Cited by 7
Self-citation
Clinical features of 280 hospitalized patients with lymphangioleiomyomatosis in J apan
Hasegawa, W., Yamauchi, Y., Yasunaga, H., Sunohara, M., Jo, T., Matsui, H., Fushimi, K., Takami, K., & Nagase, T. (2014) · Respirology · doi:10.1111/resp.12430 · Cited by 7
Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2
Goldberg, A. A., Joung, K.-B., Mansuri, A., Kang, Y., Echavarría, R., Nikolajev, L., Sun, Y., Yu, J. J., Laporte, S. A., Schwertani, A. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10748 · Cited by 7
Consequences of delay in screening, monitoring, and treatment of angiomyolipoma and tuberous sclerosis: A case report
Gipson, T. T. (2018) · Clinical Nephrology · doi:10.5414/cn109382 · Cited by 7
Lymphangioleiomyomatosis: New Treatment Perspectives
Radzikowska, E. (2015) · Lung · doi:10.1007/s00408-015-9742-6 · Cited by 7

Authors: McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., Brown, K. K., Lynch, J. P., Goldberg, H. J., Young, L. R., Kinder, B. W., Downey, G. P., Sullivan, E. J., Colby, T. V., McKay, R. T., Cohen, M. M., Korbee, L., Taveira-DaSilva, A. M., Lee, H.-S., Krischer, J. P., & Trapnell, B. C.
Affiliations: University of Cincinnati (US)
National Hospital Organization (JP)
National Institutes of Health (US)
University of Toronto (CA)
Medical University of South Carolina (US)
Niigata University Medical and Dental Hospital (JP)
Oregon Health & Science University (US)
Cleveland Clinic (US)
University of Florida (US)
The University of Texas Health Science Center at Tyler (US)
National Jewish Health (US)
Cincinnati Children's Hospital Medical Center (US)
Harvard University (US)
United Therapeutics (United States) (US)
Mayo Clinic (US)
University of South Florida (US)
ORCID: McCormack, Francis X.
Inoue, Yoshikazu
Moss, Joel
Singer, Lianne G.
Strange, Charlie
Nakata, Koh
Brantly, Mark L.
Brown, Kevin K.
Goldberg, Hilary J.
Young, Lisa R.
Downey, Gregory P.
Colby, Thomas V.
Lee, Hye-Seung
Krischer, Jeffrey P.
Trapnell, Bruce C.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2011-04-28
Volume: 364
Issue: 17
Pages: 1595-1606
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1100391
PMC: PMC3118601
OpenAlex: W2147028601
Semantic Scholar: 0af4a52c455e626ae3c70aa2ba2d64208b19a305
Cited by: 1,099
References: 27
Citations by year: 2026: 38 · 2025: 54 · 2024: 77 · 2023: 70 · 2022: 80 · 2021: 70 · 2020: 72 · 2019: 78 · 2018: 77 · 2017: 65 · 2016: 78 · 2015: 87 · 2014: 71 · 2013: 81 · 2012: 68
FWCI: 54.96
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Tuberous Sclerosis Alliance
Pfizer
LAM Foundation
Cincinnati Children's Hospital Medical Center
National Institutes of Health (1ul1rr026314-01, 1UL1RR026314)
U.S. Food and Drug Administration (FD003362, R01 FD003362)
Canadian Institutes of Health Research
National Heart, Lung, and Blood Institute (R01HL085453, ZIAHL002541)
National Center for Research Resources (1UL1 RR-026314-01, U54RR019259, UL1-RR026314, U54RR019498, RR019498, RR019259)
NHLBI Division of Intramural Research
Topics: Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
Health Sciences › Medicine › Surgery › Vascular Malformations and Hemangiomas
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords: lymphangioleiomyomatosis, rapamycin, mTOR signaling, lung function, FEV1, VEGF-D, quality of life, adverse events, drug discontinuation, cystic lung disease
MeSH terms: Adult, Double-Blind Method, Female, Forced Expiratory Volume, Humans, Middle Aged, Quality of Life, Vital Capacity, Lymphangioleiomyomatosis, Observation, Sirolimus, Medication Adherence, Intention to Treat Analysis, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks